Idience

Executive Summary

Idience is a science-driven biopharmaceutical company headquartered in San Diego, California, operating as a wholly owned subsidiary of the Korean pharmaceutical conglomerate Ildong Holdings. Founded in 2018, the company is dedicated to the development of innovative small molecule oncology therapies with a core mission to improve cancer patients' quality of life through precision medicine. By leveraging Ildong's resources and expertise, Idience aims to translate cutting-edge scientific discoveries into novel therapeutic options. While the company maintains a low public profile, its focus on small molecule modalities and precision medicine aligns with current trends in oncology, potentially positioning it for meaningful contributions to cancer treatment. Despite being in early stages, Idience benefits from the backing of a established parent company, which may provide financial stability and strategic guidance. However, the lack of publicly disclosed pipeline data, clinical trial information, or regulatory milestones limits visibility into its near-term prospects. The company's success will depend on advancing its preclinical and clinical programs, securing partnerships, and demonstrating efficacy in targeted oncology indications. With a lean operational model and a strong scientific foundation, Idience represents a niche player in the competitive oncology landscape, though substantial validation is still required.

Upcoming Catalysts (preview)

• Q3 2026First IND Filing for Lead Program30% success
• Q4 2026Preclinical Data Presentation at Major Conference50% success
• TBDStrategic Partnership or Licensing Deal20% success